试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- A
- 入组人数
- 52
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •Participating center: in which treatment-naïve Rb patients are seen and treated by any means. There is no lower or upper limit to the number of Rb patients seen in a center in order for it to become a participating center in the study. We are aiming to reach out and include as many Rb centers from around the world.
- •Subjects: All Rb patients that presented to a participating center from 01/01/2017-31/12/2017 and were offered/received treatment of any type (i.e. focal therapy, surgery, chemotherapy, radiotherapy, palliative approach (i.e. no intervention)).
排除标准
- •Patients that presented following primary treatment given/offered elsewhere.
研究者
相似试验
已完成
不适用
Retinoblastoma Biomarker StudyMelanomaSarcomaRetinoblastomaNCT00342797National Cancer Institute (NCI)2,136
招募中
不适用
Retinoblastoma Patient Clinical Database and Tissue RepositoryRetinoblastoma BilateralRetinoblastoma UnilateralRetinoblastomaNCT04959097Children's Hospital Los Angeles800
招募中
早期 1 期
Targeting NUDT21 siRNA Drugs for Patients With Refractory RetinoblastomaRefractoryRetinoblastomaNCT06424301Eye & ENT Hospital of Fudan University2
进行中（未招募）
不适用
EW CONSERVATIVE THERAPIES IN RETINOBLASTOMA: DIRECT INTRAARTERIAL (OPHTALMIC ARTERY) CHEMOTHERAPY WITH MELPHALAN FOR INTRAOCULAR RETINOBLASTOMA - ART-OFT-RTB-SI-2008EUCTR2008-005583-14-ITAZIENDA OSPEDALIERA SENESE
已完成
不适用
Molecular Analysis of RetinoblastomaRetinoblastomaNCT00718783St. Jude Children's Research Hospital41